menu
    • menu
    [{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Lacerta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AAV Capsid-based Therapeutic","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Prevail Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Prevail Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.73999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Prevail Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prevail Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Scribe Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CRISPR-based Genetic Medicine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Prevail Therapeutics","amount2":1.5800000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.5800000000000001,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prevail Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Adeno-associated Virus Gene Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Prevail Therapeutics","amount2":1.1899999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.1899999999999999,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prevail Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prevail Therapeutics","amount2":0.56000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prevail Therapeutics \/ Prevail Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Prevail Therapeutics

    Menu

    Prevail Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Precision BioSciences

                            Deal Size : $555.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Precision BioSciences Announces Return of Programs and End of Collaboration with Prevail

                            Details : Precision exercised its option to regain rights for the programs, including its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $100.0 million

                            April 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Precision BioSciences

                            Deal Size : $555.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adeno-associated Virus Gene Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Sangamo Therapeutics

                            Deal Size : $1,190.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sangamo Therapeutics Announces Research Evaluation and Option Agreement with Prevail, a Wholly Owned Subsidiar...

                            Details : Under the agreement, Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 17, 2023

                            Lead Product(s) : Adeno-associated Virus Gene Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Sangamo Therapeutics

                            Deal Size : $1,190.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRISPR-based Genetic Medicine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Scribe Therapeutics

                            Deal Size : $1,575.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-...

                            Details : Under the collaboration, Prevail gets exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified genetic targets known to cause serious neurological and neuromuscular diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $75.0 million

                            May 16, 2023

                            Lead Product(s) : CRISPR-based Genetic Medicine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Scribe Therapeutics

                            Deal Size : $1,575.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Capsida

                            Deal Size : $740.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to...

                            Details : Delivering AAV gene therapy systemically to target the CNS, while limiting exposure to non-target organs (such as the liver), has been a significant challenge in the gene therapy field.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $55.0 million

                            January 04, 2023

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Capsida

                            Deal Size : $740.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV Capsid-based Therapeutic

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Lacerta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS D...

                            Details : The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases. As a part of the collaboration, Prevail will receive rights to utilize one of Lacerta’s novel AAV capsids for select undisclosed CNS targets.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 23, 2022

                            Lead Product(s) : AAV Capsid-based Therapeutic

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Lacerta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $1,040.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Completes Acquisition of Prevail Therapeutics

                            Details : Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenera...

                            Brand Name : PR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 22, 2021

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $1,040.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $1,040.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Announces Agreement to Acquire Prevail Therapeutics

                            Details : Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disea...

                            Brand Name : PR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $1,040.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PR006,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemp...

                            Details : PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.

                            Brand Name : PR006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 30, 2020

                            Lead Product(s) : PR006,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

                            Details : The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for...

                            Brand Name : PR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 18, 2020

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prevail Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gau...

                            Details : The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.

                            Brand Name : PR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 27, 2020

                            Lead Product(s) : PR001,Methylprednisolone,Sirolimus

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth